Bronchial carcinoma: Added benefit of crizotinib not proven
The dossier contains no data or no suitable data on ROS1-positive, advanced non-small cell lung cancer. Results on ALK-positive tumors are not applicable.
Source: ScienceDaily Headlines - Category: Science Source Type: news
More News: Bronchial Tumour | Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Non-Small Cell Lung Cancer | Science